Peplin into Phase III

By Dylan Bushell-Embling
Tuesday, 09 September, 2008

Peplin [ASX: PLI] has begun a Phase III trial of its PEP005 gel for solar keratoses, common pre-cancerous skin lesions.

The trial will examine the efficacy of the gel when applied to locations other than the head. It will be simultaneously conducted in sites in Australia and the US.

The trial is being conducted with a Special Protocol Assessment from the US FDA, which ensures that the results of the study may be submitted to the FDA as part of the basis of a new drug application.

Around 250 participants are expected take part in the trial of PEP005, an ingenol mebutate gel.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd